Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

• In Figure 2, panel C was incorrect (duplicating panel B). The correct version of Figure 2 now appears in the article and is presented here. • In Figure 5, on page 6, a single point estimate marker was omitted from Figure 5. The correct version of Figure 5 now appears in the article and is presented here. • On page 6, left column, first paragraph, line 7, “(HR 1.22; 95% CI 0.92 to 1.62, P=0.16)” has been corrected to “(HR 1.24; 95% CI 0.92 to 1.66, P=0.16).” • In Figure 6, on page 7, the total number of eGFR≥60 was presented as 17073 and has been corrected to 17037. • In the legends to Figures 5 and 6, on pages 6 and 7, respectively, the following explanatory note has been added: “The prior stent subgroup is limited to those who underwent percutaneous revascularization.”